Section 350. DUR Committee  


Latest version.
  • A. The director shall provide for the establishment of a DUR Committee either directly or through a contract with an outside vendor. The DUR Board may serve as the DUR Committee.

    B. The membership of the DUR Committee shall include health care professionals who have recognized knowledge and expertise in one or more of the following:

    1. The clinically appropriate prescribing of covered drugs;

    2. The clinically appropriate dispensing and monitoring of covered drugs;

    3. Drug use review, evaluation, and intervention; and

    4. Medical quality assurance.

    C. The membership of the DUR Committee shall include physicians, pharmacists, and other health care professionals.

    D. Activities of the DUR Committee shall include, but not be limited to, the following:

    1. The review of patient, pharmacist, and physician exceptional drug utilization profiles generated from retrospective reviews applying knowledge and experience as a professional and the retrospective criteria and standards approved by the DUR Board;

    2. Develop and recommend modifications to the prospective and retrospective standards based on clinical experience, new literature findings, and communications from practitioners pursuant to the educational program;

    3. In instances where an exceptional drug use pattern is suggestive of fraud or abuse, make referrals in a manner consistent with the rules adopted by the DUR Board to the appropriate intra agency division;

    4. Provide technical expertise to assist DMAS staff in the compilation of reports and recommendations to be presented to the DUR Board and the director.

    E. The DUR Committee shall adhere to all the requirements of client confidentiality with respect to patient specific information.

Historical Notes

Derived from VR460-04-4.2600 § 9, eff. June 16, 1993.

Statutory Authority

§ 32.1-325 of the Code of Virginia.